The Experimental Therapeutics (ET) Program is organized to facilitate transdisciplinary collaborations and to accelerate the progress of patient-oriented research to clinical translation and care of patients with cancer.
The ET Program is organized into two themes: 1) Drug Discovery/Drug Delivery, where program members work to discover new agents that can be developed into drugs used to target cancer cells; and 2) Clinical Research, where program members ensure the execution of clinical research at HCI and the translation of important Cancer Center discoveries to human applications. Program goals fall within these two themes and include the following:
Program projects include development of targeted chemotherapeutic agents, second-generation polymeric carriers of anti-cancer drugs, design of macromolecular-targeted therapeutics with selective inhibitory effects on various types of malignancies, biomarker development for diagnosis, prognosis, staging, and response to therapy, and development of an active Phase I clinical trial program.
The ET Program is led by Sunil Sharma, MD, who provides the interdisciplinary clinical and scientific expertise necessary to integrate research efforts across program membership with diverse research interests. The Program facilitates linking of basic science resesarch to clinical oncology with the resulting outcome being of a significant programmatic interest in investigator-initiated trials for imaging, diagnostics, and therapeutics.
The Experimental Therapeutics Program received $14.8 million in total research support from the National Institutes of Health, the American Cancer Society, the National Science Foundation, and other funding agencies in 2013, with 28% coming from the National Cancer Institute. Cancer-focused articles published between 2009-2013 total 550, of which 28% involved collaborations with other Cancer Center members and 66% involved external partnerships.
|Sunil Sharma, MD
|HCI, Room 3380
|Agarwal, Jayant||Plastic surgery and reconstructive microsurgery.|
|Agarwal, Neeraj||Prostate and kidney cancers|
|Akerley, Wallace||Experimental therapeutics, clinical trials in oncology|
Developing new modalities for the detection of sentinel lymph nodes in patients with melanoma and breast cancer.
|Atanackovic, Djordje||Development of novel immunotherapeutic approaches including tumor vaccinations, immunomodulatory antibodies, and the adoptive transfer of receptor-modified T cell.|
|Bae, You Han||Anticancer drug carrier design targeting MDR|
|Barnette, Phillip||Acute childhood leukemia, therapeutic advances in childhood leukemia|
|Bernard, Philip||Molecular diagnostics of solid and soft tumors||website|
|Bronner, Mary||Cancerous cell growth in the gastrointestinal tract|
|Chen, Mingnan||Polypeptide-based nanoparticles to delivery cancer-stem cell-specific drugs to halt drug resistance or/and metastasis|
|Chou, Danny||Pharmaceutics and pharmaceutical chemistry|
|Cohen, Adam||Personalizing treatment decisions for brain and breast cancer|
|Colman, Howard||Treatment of primary and metastatic brain tumors|
My Research Interests are in Bone Marrow Transplantation. Participating in the are of acute and chronic graft-versus-host disease.
Molecular therapy of hematologic malignancies: target and drug discovery; biomarkers to predict clinical response.
The development of DNA-Encoded libraries as an advanced tool for drug discovery and the pursuit of ligand-targeted therapeutics as anticancer drugs.
Radiotherapy for gynecology; breast; lymphoma.
|Garrido-Laguna, Ignacio||Pancreatic ductal adenocarcinoma (PDA)|
|Ghandehari, Hamid||Design of new polymers for gene therapy of head and neck cancer|
|Grossmann, Kenneth||Demathalyse enzyme complex and other signaling pathways in melanoma tumors|
Bladder cancer and to develop a bladder cancer research program.
|Halwani, Ahmad||Immunotherapy/immunomodulation as a therapeutic modality for cancer treatment|
Molecular imaging; PET imaging; imaging of cancer-associated physiologic changes and complications.
Cancer genetics; marine natural products.
Development of novel, mainly nanotechnology- based systems for clinical cancer therapy.
|Jensen, Randy||Brain tumor angiogenesis and hypxoxia||website|
|Kadrmas, Dan||Biomaterials and drug delivery, positron emission tomography (PET) imaging|
|Khong, Hung||Cancer immuntherapy epigenetic modulation|
|Kim, Sung Wan||Medical polymers and drug delivery, angiogenesis targeting|
|Kopecek, Jindrich||Biomaterials and drug delivery|
|Kovacsovics, Tibor||Prevention and treatment of Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) and Multiple Myeloma|
|Looper, Ryan||Synthesis of new compounds with under-utilized or under-appreciated mechanisms of action, with a particular interest in natural product-inspired compounds that cause zinc-dyshomeostasis in cancer cells.|
|Morrell, Glen||Breast MRI and MRI characterization of breast cancer|
Molecular imaging; PET imaging; Imaging of cancer-associated physiologic changes and complications
|Mulvihill, Sean||Biology of pancreatic cancer|
Creating biopharmaceuticals (e.g. antibodies, growth factors) that can be used for cancer diagnosis and treatment.
MR angiography; MRI scanner design; MRI guided thermal ablation of tumors
Innovations in nanotechnology for creating ultrasensitive and real-time assays to detect cancer markers including PSA and pancreatic cancer
|Raetz, Elizabeth Ann||
Treatment of all pediatric cancers and hematologic disorders, with an emphasis on acute lymphoblastic leukemia (ALL) and lymphoma.
|Randall, R. Lor||Genetics of sarcoma||website|
Pancreas cancer modeling; mechanisms of metastases.
Nitric oxide and hematopoietic cell biology; acute leukemia; myelodysplastic syndromes
Phase I clinical trials, development and testing of new cancer therapies; treatment of patients with gastrointestinal cancers and rare tumors.
Intrinsic radiosensitivity of human tumors; mechanisms of intrinsic cellular resistance to radiation and chemotherapy and combined chemotherapy/radiotherapy.
Development of the new treatment strategies for malignant lymphomas.
Development of targeted therapeutics for advanced cancers; design of theranostics for cancer imaging and therapy.
Breast cancer prevention trials; breast cancer treatment guidelines.
|Werner, Theresa||High risk breast/ovarian cancer|
Evaluation and characterization of therapeutic response using imaging biomarkers.